Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled the release of its Q1 2025 financial results for Tuesday, May 13, 2025, before market opening. The company will provide a comprehensive update including the quarter's key achievements, recent accomplishments, and financial performance for the period ending March 31, 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in malattie rare e orfane, in fase clinica avanzata, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025, prima dell'apertura dei mercati. La società fornirà un aggiornamento completo che includerà i principali traguardi del trimestre, i recenti successi e la performance finanziaria del periodo terminato il 31 marzo 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en enfermedades raras y huérfanas en etapa clínica avanzada, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025, antes de la apertura del mercado. La compañía ofrecerá una actualización completa que incluirá los logros clave del trimestre, los recientes éxitos y el desempeño financiero del período que finaliza el 31 de marzo de 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 희귀 및 고아 질환을 전문으로 하는 후기 임상 단계 전문 제약 회사로, 2025년 1분기 재무 결과를 2025년 5월 13일 화요일 시장 개장 전에 발표할 예정입니다. 회사는 2025년 3월 31일로 종료된 분기의 주요 성과, 최근 성취 및 재무 실적에 대한 종합적인 업데이트를 제공할 것입니다.
Quoin Pharmaceuticals (NASDAQ : QNRX), une société pharmaceutique spécialisée en phase clinique avancée dans les maladies rares et orphelines, a prévu la publication de ses résultats financiers du premier trimestre 2025 le mardi 13 mai 2025, avant l'ouverture des marchés. La société fournira une mise à jour complète incluant les principales réalisations du trimestre, les succès récents et la performance financière pour la période se terminant le 31 mars 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein spezialisiertes Pharmaunternehmen in der späten klinischen Phase, das sich auf seltene und Waisenkrankheiten spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025, vor Börsenöffnung geplant. Das Unternehmen wird ein umfassendes Update zu den wichtigsten Errungenschaften des Quartals, den jüngsten Erfolgen und der finanziellen Performance für den Zeitraum bis zum 31. März 2025 bereitstellen.
- None.
- None.
ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q1 2025 earnings?
What is Quoin Pharmaceuticals' (QNRX) business focus?
What will be included in Quoin Pharmaceuticals' (QNRX) Q1 2025 earnings release?
What period will Quoin Pharmaceuticals' (QNRX) Q1 2025 financial results cover?
